Revision 1
Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
:

:

:

:

UniProt ID:

#P04637, #P19022, #Q16665, #P12004, #P08670, #P06400, #P46527, #P16422, #P12830, #P16070, #P46013, #P08575, #P00533, #P33151, #P08581, #P04626, #P15941, #O15392, #P16284

Entrez-Gene Id:

7157, 1000, 3091, 5111, 7431, 5925, 1027, 4072, 999, 960, 4288, 5788, 1956, 1003, 4233, 2064, 4582, 332, 5175

Product Information

Specificity / Sensitivity

PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) detects the target proteins as specified on the Array Target Map. No substantial cross-reactivity has been observed between targets. This kit is optimized for cell lysates diluted to a total protein concentration between 0.2 and 1 mg/ml (see kit protocol). All sandwich assays have been validated for human derived samples. This kit detects proteins from the indicated species as determined through in-house testing, but may also detect homologous proteins from other species.

Species Reactivity:

Human

Product Description

The PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) uses glass slides as the planar surface and is based upon the sandwich immunoassay principle. The array kit allows for the simultaneous detection of 19 cancer cell associated proteins. Target-specific capture antibodies have been spotted in duplicate onto nitrocellulose-coated glass slides. Each kit contains two slides allowing for the interrogation of 32 different samples and the generation of 608 data points in a single experiment. Cell lysates are incubated on the slide followed by a biotinylated detection antibody cocktail. DyLight 680-linked Streptavidin is then used to visualize the bound detection antibody. A fluorescent image of the slide can then be captured with a digital imaging system and spot intensities quantified using array analysis software.

Background

Despite shared hallmarks and common overarching principles, cancers are heterogeneous in nature. Widely used tumor derived cell lines often exhibit both genomic and proteomic differences relative to one another. Factors contributing to these differences include gradual accumulation of genetic lesions within cell lines, transcriptional networks and epigenetic marks remaining from the original tissue, and various adaptations to in vitro culture conditions. Cell lines may differ considerably in the architectural details of basic machineries, the wiring of signal transduction circuitry, and the set points of metabolic pathways. As a result, heterogeneous phenotypes within cell lines will manifest as differences in fundamental cellular functions and a range of behaviors under experimental conditions.
The cell surface represents a compartment where a high level of heterogeneity is displayed. Cancer cells can use the wide array of cell surface proteins to sense, attract, and respond to survival or growth factors in order to promote cancer cell proliferation and growth. Certain cell surface molecules can shield cancer cells from the immune response, help to procure nutrients and create more favorable conditions, and provide a means for the spread and colonization of the cancer cells to other tissues. The presence (or absence) of specific cellular proteins can be regarded as a characteristic phenotypic trait that allows for the classification of cancer cell type and may help predict cellular response to specific experimental conditions both in vitro and in vivo.
Understanding and modeling tumor cell behavior, sensitivity and resistance to various drugs, identification of oncogene dependencies and network vulnerabilities requires a systems-level measurement of multiple parameters. Therefore, it is important to simultaneously survey both the cell surface as well as key molecules that serve as indicators for cell cycle progression, epithelial to mesenchymal transition, and activation of the hypoxic response program.

  1. Scheel, C. and Weinberg, R.A. (2012) Semin Cancer Biol 22, 396-403.
  2. Hale, J.S. et al. (2012) Cell Adh Migr 6, 346-55.
  3. Varga, J. et al. (2014) FEBS Lett 588, 2422-7.
  4. Zöller, M. (2011) Nat Rev Cancer 11, 254-67.
  5. van Roy, F. (2014) Nat Rev Cancer 14, 121-34.
  6. Schnell, U. et al. (2013) Biochim Biophys Acta 1828, 1989-2001.
  7. Kufe, D.W. (2013) Oncogene 32, 1073-81.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a registered trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

使用に関する制限

法的な権限を与えられたCSTの担当者が署名した書面によって別途明示的に合意された場合を除き、 CST、その関連会社または代理店が提供する製品には以下の条件が適用されます。お客様が定める条件でここに定められた条件に含まれるものを超えるもの、 または、ここに定められた条件と異なるものは、法的な権限を与えられたCSTの担当者が別途書面にて受諾した場合を除き、拒絶され、 いかなる効力も効果も有しません。

研究専用 (For Research Use Only) またはこれに類似する表示がされた製品は、 いかなる目的についても FDA または外国もしくは国内のその他の規制機関により承認、認可または許可を受けていません。 お客様は製品を診断もしくは治療目的で使用してはならず、また、製品に表示された内容に違反する方法で使用してはなりません。 CST が販売または使用許諾する製品は、エンドユーザーであるお客様に対し、使途を研究および開発のみに限定して提供されるものです。 診断、予防もしくは治療目的で製品を使用することまたは製品を再販売 (単独であるか他の製品等の一部であるかを問いません) もしくはその他の商業的利用の目的で購入することについては、CST から別途許諾を得る必要があります。 お客様は以下の事項を遵守しなければなりません。(a) CST の製品 (単独であるか他の資材と一緒であるかを問いません) を販売、使用許諾、貸与、寄付もしくはその他の態様で第三者に譲渡したり使用させたりしてはなりません。また、商用の製品を製造するために CST の製品を使用してはなりません。(b) 複製、改変、リバースエンジニアリング、逆コンパイル、 分解または他の方法により製品の構造または技術を解明しようとしてはなりません。また、 CST の製品またはサービスと競合する製品またはサービスを開発する目的で CST の製品を使用してはなりません。(c) CST の製品の商標、商号、ロゴ、特許または著作権に関する通知または表示を除去したり改変したりしてはなりません。(d) CST の製品をCST 製品販売条件(CST’s Product Terms of Sale) および該当する書面のみに従って使用しなければなりません。(e) CST の製品に関連してお客様が使用する第三者の製品またはサービスに関する使用許諾条件、 サービス提供条件またはこれに類する合意事項を遵守しなければなりません。

Revision 1
#14822

PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout)

PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout): Image 1 Expand Image
Figure 1. Target Map of the PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) #14822.
PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout): Image 2 Expand Image
Figure 2. HeLa and A-431 cells (Panel A), and HCC827 and Calu-3 cells (Panel B) were grown to 90% confluency. Cell Lysates were prepared and analyzed using PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) #14822. Array fluorescent images were acquired using the LI-COR® Biosciences Odyssey® Imaging System (upper) and fluorescence intensities for each spot were quantified using the LI-COR® Image Studio v2.0 array analysis software and depicted as bar graphs (lower).
PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout): Image 3 Expand Image
Figure 3. A-431 cells were treated for five days with a cocktail of EMT inducers. Cell lysates were prepared and analyzed using the PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) #14822. Array fluorescent images were acquired using the LI-COR® Biosciences Odyssey® imaging system (upper) and fluorescence intensities for each spot were quantified using the LI-COR® Image Studio v2.0 array analysis software and depicted as a bar graph (lower).
PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout): Image 4 Expand Image
Figure 4. Various cells (indicated) were grown and cell extracts were prepared and analyzed using the PathScan® Cancer Phenotype Antibody Array Kit (Fluorescent Readout) #14822. Slides were scanned using the LI-COR® Biosciences Odyssey CLx infrared imaging system. Fluorescence intensity for each spot was quantified using the LI-COR® Biosciences Image Studio v2.0 array analysis software. Duplicate spot intensities were averaged and values were normalized after subtracting the background signal. The heatmap was generated using MultiExperiment Viewer (MeV) analysis software.